tiprankstipranks
Faron Pharmaceuticals Oy (GB:FARN)
LSE:FARN
Holding GB:FARN?
Track your performance easily

Faron Pharmaceuticals Oy (FARN) Share Forecast & Price Target

29 Followers
See the Price Targets and Ratings of:

FARN Analyst Ratings

Hold
2Ratings
1 Buy
0 Hold
1 Sell
Based on 2 analysts giving stock ratings to
Faron
Pharmaceuticals Oy
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FARN Stock 12 Month Forecast

Average Price Target

537.62p
▲(277.28% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Faron Pharmaceuticals Oy in the last 3 months. The average price target is 537.62p with a high forecast of 1,000.00p and a low forecast of 75.24p. The average price target represents a 277.28% change from the last price of 142.50p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"74":"74p","1001":"1,001p","305.75":"305.8p","537.5":"537.5p","769.25":"769.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":537.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">537.62p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75.23811,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">75.24p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[74,305.75,537.5,769.25,1001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165,229.23076923076923,293.46153846153845,357.6923076923077,421.9230769230769,486.15384615384613,550.3846153846154,614.6153846153845,678.8461538461538,743.0769230769231,807.3076923076923,871.5384615384614,935.7692307692307,{"y":1000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165,193.66307692307691,222.32615384615383,250.98923076923077,279.65230769230766,308.3153846153846,336.97846153846154,365.64153846153846,394.3046153846154,422.9676923076923,451.6307692307692,480.2938461538461,508.9569230769231,{"y":537.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,165,158.09523923076924,151.19047846153848,144.28571769230768,137.38095692307692,130.47619615384616,123.5714353846154,116.66667461538462,109.76191384615385,102.85715307692308,95.95239230769232,89.04763153846154,82.14287076923078,{"y":75.23811,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":226.66,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":277.12,"date":1702598400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":244.04,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237.42,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.15,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.61,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":124.09,"date":1714694400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":96,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":94,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.5,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":224,"date":1725580800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":222,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":165,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target1,000.00pAverage Price Target537.62pLowest Price Target75.24p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article

Best Analysts Covering Faron Pharmaceuticals Oy

Which Analyst Should I Follow If I Want to Buy GB:FARN and Sell After:
1 Month
xxx
Success Rate
2/6 ratings generated profit
33%
Average Return
-11.93%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of -11.93% per trade.
3 Months
xxx
Success Rate
1/6 ratings generated profit
17%
Average Return
-15.67%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -15.67% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
2/6 ratings generated profit
33%
Average Return
-18.70%
reiterated a buy rating 29 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -18.70% per trade.
2 Years
xxx
Success Rate
2/6 ratings generated profit
33%
Average Return
-18.70%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -18.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FARN Analyst Recommendation Trends

Rating
May 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
0
0
0
0
0
Buy
3
3
2
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
1
1
1
1
1
total
4
4
3
3
3
In the current month, FARN has received 2 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. FARN average Analyst price target in the past 3 months is 537.62p.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FARN Financial Forecast

FARN Earnings Forecast

Next quarter’s earnings estimate for FARN is -0.13p with a range of -0.13p to -0.12p. The previous quarter’s EPS was -0.17p. FARN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.67% of the time in the same period. In the last calendar year FARN has Outperformed its overall industry.
Next quarter’s earnings estimate for FARN is -0.13p with a range of -0.13p to -0.12p. The previous quarter’s EPS was -0.17p. FARN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.67% of the time in the same period. In the last calendar year FARN has Outperformed its overall industry.

FARN Sales Forecast

Next quarter’s sales forecast for FARN is 0.00p with a range of 0.00p to 0.00p. The previous quarter’s sales results were 0.00p. FARN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 44.59% of the time in the same period. In the last calendar year FARN has Underperformed its overall industry.
Next quarter’s sales forecast for FARN is 0.00p with a range of 0.00p to 0.00p. The previous quarter’s sales results were 0.00p. FARN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 44.59% of the time in the same period. In the last calendar year FARN has Underperformed its overall industry.

FARN Stock Forecast FAQ

What is GB:FARN’s average 12-month price target, according to analysts?
Based on analyst ratings, Faron Pharmaceuticals Oy’s 12-month average price target is 537.62p.
    What is GB:FARN’s upside potential, based on the analysts’ average price target?
    Faron Pharmaceuticals Oy has 277.28% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Faron Pharmaceuticals Oy a Buy, Sell or Hold?
          Faron Pharmaceuticals Oy has a consensus rating of Hold, which is based on 1 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Faron Pharmaceuticals Oy’s share price target?
            The average share price target for Faron Pharmaceuticals Oy is 537.62p. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 1,000.00p ,and the lowest forecast is 75.24p. The average share price target represents 277.28% Increase from the current price of 142.5p.
              What do analysts say about Faron Pharmaceuticals Oy?
              Faron Pharmaceuticals Oy’s analyst rating consensus is a Hold. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Faron Pharmaceuticals Oy?
                To buy shares of GB:FARN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis